Melatonin: Mechanism, Research and Reported Effects

Melatonin is not a sedative. It is a darkness signal. The pineal gland releases it when light stops reaching specialised retinal cells, and nearly every effect described in the literature follows from that timing cue rather than from any direct depressant action on the central nervous system.

Our team reads this literature constantly, and the gap between how melatonin gets marketed and what the research actually describes is unusually wide. Real Peptides does not carry melatonin. This page exists because researchers keep asking what the evidence says.

What is melatonin?

Melatonin is N-acetyl-5-methoxytryptamine, an indoleamine hormone synthesised from tryptophan in the pineal gland and released in response to darkness. It acts mainly through the MT1 and MT2 receptors to entrain circadian timing. Its elimination half-life is short, generally reported in the range of roughly 20 to 60 minutes.

The most common misconception is that melatonin belongs in the same category as hypnotic drugs. It does not. A second misconception, which drives a surprising share of search traffic, is that melatonin is a peptide. It is not, and the distinction matters for storage, handling and analytical verification. This page covers what the molecule is, how the receptor mechanism works, what the published literature reports on circadian and non-circadian roles, what side effects and toxicity questions researchers have raised, the pharmacokinetic picture, and how a laboratory verifies identity and purity before any material enters a study.

What is melatonin, exactly?

Melatonin is a small indoleamine with the molecular formula C13H16N2O2 and a molecular weight of roughly 232 g/mol. Its biosynthesis runs through a four-step pathway: tryptophan is hydroxylated and decarboxylated to serotonin, then arylalkylamine N-acetyltransferase (AANAT) converts serotonin to N-acetylserotonin, and acetylserotonin O-methyltransferase adds the methoxy group that produces melatonin.

Melatonin is amphiphilic, meaning it moves through both lipid membranes and aqueous compartments without needing a transporter. It crosses the blood-brain barrier and the placenta freely. A 2014 review in Physiology described the molecule as exceeding expectations precisely because its distribution is so unrestricted compared with most signalling hormones (PMID 25180262).

Synthesis is gated by light. Retinal ganglion cells containing melanopsin project to the suprachiasmatic nucleus (SCN), which relays through the superior cervical ganglion to the pineal gland. Light suppresses the signal. Darkness releases it. Work published in the Journal of Applied Physiology in 2011 showed that blue light from light-emitting diodes suppresses melatonin in humans (PMID 21164152).

Melatonin does not tell an organism to sleep. It tells an organism what biological time it is, and sleep behaviour in diurnal species is one downstream consequence among many.

Is it a peptide, a hormone, or something else?

Melatonin is a hormone, specifically an indoleamine neurohormone. It is not a peptide. Peptides are chains of amino acids joined by peptide bonds; melatonin contains no peptide bond at all. It is derived from a single amino acid, tryptophan, which is why the phrase melatonin peptide circulates so widely and is still wrong.

The confusion has a real source. Several research peptides are studied for their effect on pineal function. Epitalon, the synthetic tetrapeptide Ala-Glu-Asp-Gly, is the clearest example, and researchers comparing it against the parent hormone often review the literature on epitalon and melatonin production side by side.

This is not a semantic quibble. The classification determines handling. Lyophilised peptides denature irreversibly above their storage threshold and need reconstitution with bacteriostatic water. Melatonin is a stable small molecule that is poorly water-soluble and far more sensitive to light and oxidation than to a brief temperature excursion. A laboratory that treats melatonin like a peptide will apply the wrong cold chain and the wrong solvent.

How does the molecule actually work?

Melatonin signals through two high-affinity G protein-coupled receptors, MT1 (gene MTNR1A) and MT2 (gene MTNR1B), both coupled to inhibitory Gi proteins. Receptor binding inhibits adenylyl cyclase, lowering intracellular cyclic AMP. The receptor field was already being mapped in detail by the late 1980s, when a review in the Journal of Neural Transmission revisited melatonin receptor pharmacology (PMID 2841420).

The two receptors do different jobs. MT1 density is highest in the SCN and the pars tuberalis of the pituitary, where activation acutely dampens neuronal firing. MT2 is implicated in phase-shifting, meaning it moves the clock forward or backward rather than simply quieting it. A third binding site, historically labelled MT3, was later identified as quinone reductase 2 (NQO2), which is not a receptor at all.

Melatonin also acts without any receptor involvement. As a direct radical scavenger it neutralises hydroxyl radicals and peroxynitrite, and its metabolites, including cyclic 3-hydroxymelatonin and N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), are themselves antioxidants. A 2022 review in Antioxidants and Redox Signaling made the discrimination between circadian and non-circadian functions explicit (PMID 35018802), and that split is the single most useful framework for reading this field.

What does the published research cover so far?

The melatonin literature is large and unevenly distributed. Circadian work is the oldest and most consistent branch. A 2017 paper in the Journal of Pineal Research examined melatonin in relation to the pathologies associated with weakened circadian oscillators (PMID 27763686). A 2025 review in Sleep Medicine Reviews explored physiological roles beyond circadian regulation (PMID 40617069).

The antioxidant and anti-inflammatory branch has grown fastest. A 2024 paper in Frontiers in Immunology characterised melatonin as a placental antioxidant and anti-inflammatory agent (PMID 38361952).

Oncology-adjacent observational work exists as well. A 2021 paper in Endocrine, Metabolic and Immune Disorders Drug Targets examined circadian rhythm and melatonin concentration in breast cancer patients (PMID 33261546). That is a concentration and rhythm observation, not a treatment finding.

On the applied side, a 2025 review in Sleep and Breathing collected new insights on melatonin supplementation across health and disease (PMID 40278958), while a 2021 paper in the International Journal of Molecular Sciences traced the path from pharmacokinetics to clinical use in autism spectrum disorder (PMID 33540815).

What side effects and unknowns does the literature report?

The reported adverse effect profile in the published literature is mild and short-lived in most reviews, with headache, daytime grogginess, dizziness and gastrointestinal upset appearing most often. That is the consistent picture, and it is also where careful reading matters most, because mild does not mean absent and short-term does not mean long-term.

A 2025 paper in Chemico-Biological Interactions framed this directly as melatonin's paradox, moving from therapeutic benefits to toxicity warnings within a single review (PMID 40383469). That paper is the most honest single citation in this entire field, because it refuses to pretend the safety question is settled. A 2022 review in Nutrients asked whether melatonin is becoming the next vitamin D, covering emerging science, clinical uses, safety and the dietary supplement market (PMID 36235587).

The open questions are larger than the resolved ones. Long-term exposure data in developing organisms is limited. Interactions with hepatic enzymes, particularly CYP1A2, create a plausible mechanism for interference with other compounds. Receptor desensitisation under sustained exposure is still poorly characterised.

How long does it last in circulation?

Melatonin has a short elimination half-life, generally reported in the range of roughly 20 to 60 minutes. That is the number driving most of the confusion around this molecule, because it is far shorter than the duration of effect people expect from it.

The metabolic route explains the brevity. Exogenous melatonin is subject to extensive first-pass hepatic metabolism, primarily by CYP1A2, which hydroxylates it to 6-hydroxymelatonin. That intermediate is conjugated to 6-sulfatoxymelatonin (aMT6s), which is excreted in urine. Because aMT6s excretion tracks pineal output closely, urinary aMT6s is the standard non-invasive biomarker.

Bioavailability is low and highly variable between individuals, a consequence of first-pass effect combined with CYP1A2 activity differences driven by genetics, smoking status and caffeine intake. Two subjects in the same study can produce markedly different plasma curves from identical material.

The short half-life also means circulating melatonin is a poor proxy for exposure history. A single sample tells a researcher almost nothing. Timing of sampling relative to the light-dark cycle determines the result more than anything else.

How do researchers verify a vial before it enters a study?

Verification rests on three documents, and any one of them alone is insufficient. A certificate of analysis (COA) states what the supplier claims. High-performance liquid chromatography (HPLC) quantifies purity. Mass spectrometry confirms identity. Purity without identity confirmation only proves that a vial contains a lot of one thing, not that the thing is melatonin.

HPLC separates compounds by retention time against a reference standard, and the resulting chromatogram should show a dominant peak with quantified minor peaks. What matters is the batch number on the chromatogram matching the batch number on the vial.

Mass spectrometry, usually LC-MS, verifies molecular weight. For melatonin, the expected protonated molecular ion sits near m/z 233 for a molecule of roughly 232 g/mol. Fragmentation patterns confirm structural identity beyond the mass alone. Third-party testing matters here because the analysis is only as independent as the laboratory performing it.

We publish batch-linked certificates for every compound in our catalogue at our COA library. Melatonin is not in that catalogue, so treat our COA format as a template to measure others against.

What does sound laboratory handling look like?

Melatonin is photosensitive and oxidation-prone, which makes light exclusion the primary handling control rather than temperature. Amber glass vials, minimal ambient light exposure during weighing, and tightly sealed containers under inert headspace where possible all matter more for this molecule than they would for a lyophilised peptide.

Temperature still matters, just differently. Solid crystalline melatonin stored dry, dark and sealed is comparatively stable at controlled room temperature, while solutions degrade faster and benefit from refrigeration at 2 to 8 degrees Celsius with light protection.

Solution preparation is where most avoidable errors happen. Introducing air into a sealed vial while drawing solution creates a pressure differential that pulls ambient contaminants back through the needle. Freeze-thaw cycling is the other silent killer of sample integrity, which is why aliquoting at preparation rather than repeatedly accessing a master solution is standard practice.

What is the legal and research-use-only status?

Melatonin occupies an unusual regulatory position that differs sharply between jurisdictions. In some countries it is regulated as a prescription medicine; in others it is sold as a dietary supplement with correspondingly lighter manufacturing oversight. That inconsistency is one reason the 2022 Nutrients review devoted attention to the dietary supplement category alongside the clinical science (PMID 36235587).

Research-grade material is a separate category from both. All compounds discussed on this page are sold for research use only and are not for human consumption. Research-grade material is manufactured and documented for laboratory investigation, not for consumption, and it carries no approval for the prevention, treatment or management of any condition in any species.

Anyone with questions about melatonin in an animal health context should talk to their veterinarian rather than a research supplier, because species-specific physiology and regulatory status differ in ways no general article can address. The information here is educational and describes what published research reports; it is not guidance for use in any living subject.

Real Peptides does not stock melatonin. Our catalogue covers research peptides, and our laboratory and shipping information reflects that scope. We publish this page because the search demand for accurate melatonin information is enormous and the quality of what ranks for it is poor.

How does it compare with related research compounds?

Researchers investigating circadian or pineal biology usually encounter three distinct molecule classes that get discussed interchangeably and should not be. The table below separates them by molecular class, primary biological target, and the weight of published evidence behind each.

The practical takeaway is that only one row here has a confirmed receptor pharmacology. Study designs that treat these as interchangeable circadian tools are comparing a well-mapped hormone against two peptides with far weaker mechanistic support.

What If: Laboratory Scenarios

What if a certificate of analysis lists purity but no mass spectrometry data?

Treat the material as unverified for identity and request the LC-MS report before it enters any study. HPLC purity tells a laboratory that one compound dominates the sample; it does not confirm which compound. Without a molecular ion consistent with a 232 g/mol structure, a highly pure impurity is indistinguishable from highly pure melatonin on a chromatogram alone.

What if a melatonin solution has changed colour since preparation?

Discard it and prepare fresh material from solid stock, logging the exposure conditions that preceded the change. Yellowing in an indoleamine solution typically indicates oxidative degradation, and because melatonin's own metabolites are themselves biologically active antioxidants, a degraded solution is not inert. It is a mixture of unknown composition, which makes any downstream measurement uninterpretable.

What if results vary widely between subjects in the same pharmacokinetic study?

Check CYP1A2 activity variables before suspecting a material problem. Caffeine intake, smoking status and genetic polymorphism all alter CYP1A2 throughput, and because melatonin undergoes extensive first-pass metabolism by that enzyme, between-subject plasma variability is an expected feature of the molecule rather than a protocol failure.

The honest limits of this evidence

Here is the honest answer: melatonin is one of the best-characterised signalling molecules in human biology at the mechanistic level and one of the worst-characterised at the long-term safety level. Those two facts coexist. The receptor pharmacology has been mapped since the 1980s, the metabolic pathway is unambiguous, and the antioxidant chemistry is well described. What does not exist is a substantial body of long-duration exposure data, particularly in developing organisms. Anyone presenting melatonin as uniformly benign is extrapolating past where the literature goes, and the 2025 toxicity review exists precisely because that extrapolation became common.

How we researched this page

Every study claim on this page is linked to a specific PubMed record, and each citation is described from the paper it belongs to rather than from secondary summaries. The source set spans a 1988 receptor pharmacology review through to 2025 papers in Sleep Medicine Reviews, Sleep and Breathing, and Chemico-Biological Interactions, which gives the page both the foundational mechanism work and the current state of the safety discussion.

We make no first-party testing claims about melatonin. Real Peptides has not synthesised, assayed or independently analysed this compound, and nothing here is presented as in-house data. Where this page describes verification standards, storage behaviour or analytical documentation, it reflects laboratory practice we apply across our own research peptide catalogue, generalised to a small-molecule hormone that we do not supply. Claims that could not be tied to a verifiable source were left out rather than estimated.

Melatonin ends up being a useful test case for how to read a research literature honestly, because the molecule is simultaneously ancient in evolutionary terms, present in organisms from bacteria to mammals, and still producing new review papers in 2025 that disagree with each other about risk. A compound can be well understood and poorly characterised at the same time. That is the condition most research chemicals are actually in, and melatonin is simply the one where the gap is impossible to hide.

Further reading across this site covers supplier quality criteria for research-grade material, shipping and sourcing considerations, and research-grade alternatives researchers evaluate when sourcing online.